Could a cocktail of three drugs tame a rare paralyzing disease?
NCT ID NCT02314208
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tested three drugs—Xenbilox, Tahor, and resveratrol—in 12 adults with SPG5, a rare genetic condition causing progressive leg weakness. The goal was to lower levels of a toxic cholesterol byproduct called 27-hydroxycholesterol. Each drug was taken for 2 months, and blood levels were measured before and after treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Xenbilox (chenodeoxycholic acid), Tahor (atorvastatin), and resveratrol
- What this could lead to
- If successful, this could point toward a treatment to slow or manage SPG5 by reducing toxic oxysterol buildup.
- What could go wrong
- This is a small, early-phase trial with only 12 participants, so results may not apply to everyone. The drugs may not effectively lower oxysterols or improve symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
12 people
The number who actually took part.
- Started
-
Jan 2015
- Finished
-
Jan 2018
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * patients that have confirmed through genetic testing their status as carriers of 2 mutations in the CYP7B1 gene * age ≥ 18 years * patients that have signed the informed consent form * presence of health care coverage Exclusion Criteria: * known hypersensitvity to chenodeoxycholic acid, atorvastatin, resveratrol or to any of their byproducts * cholesterol lowering medications other than the study treatment * hepatic failure with transaminases \>3 times the normal level * progressive biliary pathology * chronic diarrhea * serious mental illness * significant comorbid neurological disorder * incapacity to understand information about the protocol * unwilling or unable to participate in any part of the study * participation in another clinical trial during the study period * person deprived of liberty by judicial or administrative decision * adult subject under legal protection or unable to consent * pregnant or breastfeeding women * lack of health care coverage * absence of a signed informed consent form
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Spastic paraplegia type 5 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pitié-Salpêtrière Hospital
Paris, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.